Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results